Therapeutic benefits of CD90-negative cardiac stromal cells in rats with a 30-day chronic infarct.
Cardiac stromal cells (CSCs) can be derived from explant cultures, and a subgroup of these cells is viewed as cardiac mesenchymal stem cells due to their expression of CD90. Here, we sought to determine the therapeutic potential of CD90-positive and CD90-negative CSCs in a rat model of chronic myocardial infarction. We obtain CD90-positive and CD90-negative fractions of CSCs from rat myocardial tissue explant cultures by magnetically activated cell sorting. In vitro, CD90-negative CSCs outperform CD90-positive CSCs in tube formation and cardiomyocyte functional assays. In rats with a 30-day infarct, injection of CD90-negative CSCs augments cardiac function in the infarct in a way superior to that from CD90-positive CSCs and unsorted CSCs. Histological analysis revealed that CD90-negative CSCs increase vascularization in the infarct. Our results suggest that CD90-negative CSCs could be a development candidate as a new cell therapy product for chronic myocardial infarction.
['Shen|Deliang|D|0000-0002-1826-5141', 'Shen|Miaoda|M|', 'Liang|Hongxia|H|', 'Tang|Junnan|J|', 'Wang|Bo|B|', 'Liu|Chuang|C|', 'Wang|Peiwen|P|', 'Dong|Jianzeng|J|', 'Li|Ling|L|', 'Zhang|Jinying|J|', 'Caranasos|Thomas G|TG|']
D000818:Animals D015415:Biomarkers D004195:Disease Models, Animal D005346:Fibroblast Growth Factors D015870:Gene Expression D020869:Gene Expression Profiling D017228:Hepatocyte Growth Factor D061307:Human Umbilical Vein Endothelial Cells D006801:Humans D018189:Immunomagnetic Separation D019394:Ki-67 Antigen D008297:Male D045164:Mesenchymal Stem Cell Transplantation D059630:Mesenchymal Stem Cells D009203:Myocardial Infarction D009206:Myocardium D032383:Myocytes, Cardiac D018919:Neovascularization, Physiologic D061251:Primary Cell Culture D051381:Rats D017207:Rats, Sprague-Dawley D018800:Thy-1 Antigens D042461:Vascular Endothelial Growth Factor A
stem cells CD90 myocardial infarction cardiac regeneration